Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 60837 | 2.48 |
09:34 ET | 121755 | 2.42 |
09:36 ET | 11012 | 2.25 |
09:38 ET | 167467 | 2.125 |
09:39 ET | 26552 | 2.06 |
09:41 ET | 26557 | 2.09 |
09:43 ET | 10626 | 2.135 |
09:45 ET | 5226 | 2.11 |
09:48 ET | 11273 | 2.075 |
09:50 ET | 22857 | 2.0673 |
09:52 ET | 13745 | 2.065 |
09:54 ET | 17236 | 2.07 |
09:56 ET | 30082 | 2.06 |
09:57 ET | 19898 | 2.085 |
09:59 ET | 6876 | 2.07 |
10:01 ET | 1500 | 2.07 |
10:03 ET | 1900 | 2.075 |
10:06 ET | 10857 | 2.0797 |
10:08 ET | 13810 | 2.085 |
10:10 ET | 2054 | 2.08 |
10:14 ET | 7100 | 2.07 |
10:15 ET | 3228 | 2.075 |
10:17 ET | 300 | 2.07 |
10:19 ET | 21230 | 2.0808 |
10:21 ET | 23153 | 2.105 |
10:24 ET | 19134 | 2.105 |
10:26 ET | 810 | 2.105 |
10:28 ET | 1900 | 2.1008 |
10:30 ET | 552 | 2.105 |
10:32 ET | 1590 | 2.1 |
10:33 ET | 5918 | 2.1 |
10:35 ET | 4036 | 2.105 |
10:37 ET | 773 | 2.115 |
10:39 ET | 14367 | 2.125 |
10:44 ET | 13202 | 2.115 |
10:46 ET | 752 | 2.115 |
10:48 ET | 9185 | 2.09 |
10:50 ET | 17272 | 2.07 |
10:51 ET | 6043 | 2.07 |
10:53 ET | 23752 | 2.065 |
10:55 ET | 400 | 2.065 |
10:57 ET | 14021 | 2.08 |
11:00 ET | 10988 | 2.085 |
11:02 ET | 7390 | 2.085 |
11:04 ET | 17746 | 2.075 |
11:06 ET | 3585 | 2.075 |
11:09 ET | 400 | 2.075 |
11:11 ET | 1600 | 2.075 |
11:13 ET | 2236 | 2.08 |
11:15 ET | 6831 | 2.065 |
11:18 ET | 5118 | 2.07 |
11:20 ET | 400 | 2.065 |
11:22 ET | 500 | 2.06 |
11:24 ET | 1000 | 2.06 |
11:26 ET | 1579 | 2.06 |
11:27 ET | 9771 | 2.05 |
11:29 ET | 16517 | 2.06 |
11:31 ET | 17138 | 2.08 |
11:33 ET | 4896 | 2.085 |
11:36 ET | 3089 | 2.085 |
11:38 ET | 7140 | 2.085 |
11:40 ET | 6568 | 2.085 |
11:42 ET | 400 | 2.1 |
11:44 ET | 700 | 2.1 |
11:45 ET | 3974 | 2.09 |
11:47 ET | 100 | 2.08 |
11:49 ET | 4200 | 2.09 |
11:51 ET | 17448 | 2.08 |
11:54 ET | 10995 | 2.08 |
11:56 ET | 5907 | 2.09 |
11:58 ET | 400 | 2.09 |
12:00 ET | 13604 | 2.085 |
12:02 ET | 922 | 2.085 |
12:03 ET | 3144 | 2.08 |
12:05 ET | 662 | 2.09 |
12:07 ET | 100 | 2.08 |
12:09 ET | 800 | 2.0825 |
12:12 ET | 2900 | 2.09 |
12:14 ET | 30624 | 2.075 |
12:16 ET | 20697 | 2.0601 |
12:18 ET | 1596 | 2.064 |
12:20 ET | 800 | 2.06 |
12:21 ET | 1199 | 2.06 |
12:23 ET | 10682 | 2.065 |
12:25 ET | 5337 | 2.08 |
12:27 ET | 400 | 2.08 |
12:30 ET | 6673 | 2.075 |
12:32 ET | 400 | 2.08 |
12:34 ET | 500 | 2.08 |
12:36 ET | 530 | 2.075 |
12:38 ET | 10980 | 2.065 |
12:41 ET | 600 | 2.06 |
12:43 ET | 5523 | 2.0689 |
12:45 ET | 500 | 2.06 |
12:48 ET | 900 | 2.065 |
12:50 ET | 700 | 2.06 |
12:52 ET | 34907 | 2.06 |
12:54 ET | 16505 | 2.085 |
12:56 ET | 100 | 2.085 |
12:57 ET | 15219 | 2.075 |
12:59 ET | 41055 | 2.09 |
01:03 ET | 550 | 2.095 |
01:06 ET | 2905 | 2.0999 |
01:08 ET | 2682 | 2.095 |
01:10 ET | 812 | 2.09 |
01:12 ET | 5222 | 2.09 |
01:14 ET | 700 | 2.09 |
01:15 ET | 1000 | 2.09 |
01:17 ET | 1593 | 2.09 |
01:19 ET | 800 | 2.09 |
01:21 ET | 6300 | 2.09 |
01:24 ET | 28321 | 2.09 |
01:26 ET | 5359 | 2.1 |
01:28 ET | 3895 | 2.1 |
01:30 ET | 1000 | 2.1 |
01:32 ET | 17795 | 2.09 |
01:33 ET | 200 | 2.095 |
01:39 ET | 1200 | 2.092 |
01:42 ET | 882 | 2.095 |
01:44 ET | 25756 | 2.12 |
01:46 ET | 5200 | 2.12 |
01:48 ET | 1600 | 2.12 |
01:50 ET | 900 | 2.12 |
01:51 ET | 300 | 2.12 |
01:53 ET | 15129 | 2.1014 |
01:57 ET | 100 | 2.1 |
02:00 ET | 1500 | 2.1025 |
02:02 ET | 5828 | 2.105 |
02:04 ET | 100 | 2.11 |
02:06 ET | 1300 | 2.11 |
02:08 ET | 513 | 2.105 |
02:09 ET | 300 | 2.11 |
02:11 ET | 200 | 2.11 |
02:13 ET | 300 | 2.105 |
02:15 ET | 1499 | 2.11 |
02:18 ET | 200 | 2.11 |
02:20 ET | 11404 | 2.085 |
02:22 ET | 300 | 2.085 |
02:24 ET | 400 | 2.085 |
02:26 ET | 673 | 2.084 |
02:27 ET | 8837 | 2.095 |
02:29 ET | 100 | 2.09 |
02:31 ET | 500 | 2.1 |
02:33 ET | 600 | 2.095 |
02:36 ET | 400 | 2.1 |
02:38 ET | 600 | 2.09 |
02:40 ET | 15928 | 2.08 |
02:42 ET | 1654 | 2.085 |
02:45 ET | 1200 | 2.08 |
02:47 ET | 600 | 2.08 |
02:49 ET | 2413 | 2.09 |
02:51 ET | 1036 | 2.085 |
02:54 ET | 4243 | 2.08 |
02:58 ET | 2242 | 2.085 |
03:00 ET | 606 | 2.085 |
03:02 ET | 1937 | 2.09 |
03:03 ET | 2484 | 2.085 |
03:05 ET | 2093 | 2.0825 |
03:07 ET | 6483 | 2.095 |
03:09 ET | 400 | 2.095 |
03:12 ET | 900 | 2.095 |
03:14 ET | 600 | 2.09 |
03:16 ET | 5567 | 2.0802 |
03:18 ET | 1600 | 2.08 |
03:20 ET | 27811 | 2.06 |
03:21 ET | 600 | 2.06 |
03:23 ET | 2200 | 2.065 |
03:25 ET | 1200 | 2.06 |
03:27 ET | 552 | 2.06 |
03:30 ET | 3550 | 2.06 |
03:32 ET | 1800 | 2.06 |
03:34 ET | 41969 | 2.03 |
03:36 ET | 1400 | 2.03 |
03:38 ET | 1500 | 2.03 |
03:39 ET | 2728 | 2.03 |
03:41 ET | 4418 | 2.035 |
03:43 ET | 10583 | 2.05 |
03:45 ET | 3207 | 2.05 |
03:48 ET | 4990 | 2.04 |
03:50 ET | 6529 | 2.04 |
03:52 ET | 3057 | 2.04 |
03:54 ET | 23841 | 2.05 |
03:56 ET | 5024 | 2.05 |
03:57 ET | 22110 | 2.05 |
03:59 ET | 13589 | 2.06 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 311.2M | -2.5x | --- |
RAPT Therapeutics Inc | 312.5M | -2.9x | --- |
Nanobiotix SA | 290.9M | -3.6x | --- |
Opthea Ltd | 320.4M | -1.7x | --- |
Verastem Inc | 298.5M | -2.9x | --- |
Adlai Nortye Ltd | 327.6M | -5.3x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. The Company’s pipeline includes five clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, a SHP2 inhibitor, an EGFR inhibitor, and a central nervous system (CNS)-penetrant KRAS G12C inhibitor, and seven discovery-stage programs targeting other key oncogenic drivers. The Company’s lead product candidate is naporafenib, designed to be a reversible, potent and selective ATP-competitive type 2 pan-RAF kinase inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $311.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 151.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.83 |
Book Value | $2.10 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.